TY  - BOOK
AU  - Asmaa Abdelaziz Mohamed Bayoumi
AU  - Magdi Ibrahim Mohamed , 
AU  - Mohamed Aly Kassem , 
TI  - A pharmaceutical study on certain poorly soluble antihypertensive drug / 
PY  - 2017///
CY  - Cairo : 
PB  - Asmaa Abdelaziz Mohamed Bayoumi , 
KW  - Antihypertensive drug
KW  - Azilsartan kamedoxomil
KW  - Certain poorly soluble
N1  - Thesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics; Issued also as CD
N2  - Azilsartan kamedoxomil is a selective angiotensin II receptor antagonist, type1 (AT1) competi-tive antagonist. The US Food and Drug Administration (FDA) has approved Edarbi tablet (Azilsartan Medoxomil Potassium) on February 25, 2011, to treat hypertension in adults. It is available in 80 mg and 40 mg dosages. Many patients may prefer the oral route of administration to the more invasive other treatment options that includes injections especially if the oral formula could achieve a rapid onset of action. Azilsartan kamedoxomil is a poorly water soluble belongs to Biopharmaceutical Classification System (BCS class IV). One of the major problems of this drug is low solubility in biological flu-ids, which results in poor bioavailability after oral administration. Hence, its solubility should be enhanced to increase its bioavailability. In this work, azilsartan kamedoxomil was formulated in the form of rapidly dissolving stable tablets using different technique
ER  -